Analyst Price Targets — ARTV
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 11, 2026 11:47 am | David Nierengarten | Wedbush | $40.00 | $11.15 | TheFly | Artiva Biotherapeutics price target raised to $40 from $23 at Wedbush |
| May 8, 2026 3:39 pm | — | H.C. Wainwright | $35.00 | $11.84 | TheFly | Artiva Biotherapeutics price target raised to $35 from $15 at H.C. Wainwright |
| August 13, 2024 7:39 am | David Nierengarten | Wedbush | $18.00 | $11.22 | TheFly | Wedbush bullish on Artiva Biotherapeutics, initiates with an Outperform |
| August 13, 2024 6:51 am | Gil Blum | Needham | $23.00 | $11.22 | TheFly | Artiva Biotherapeutics initiated with a Buy at Needham |
Latest News for ARTV
SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that the Compensation Committee of its Board of Directors approved new employee inducement grants covering an aggregate of 288,800 restricted stock…
Here is how Artiva Biotherapeutics, Inc. (ARTV) and Climb Bio, Inc. (CLYM) have performed compared to their sector so far this year.
SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that Artiva management will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on Tuesday, June 30,…
Multiple EULAR presentations reinforce potential of AlloNK to drive deep B-cell depletion and meaningful clinical responses across refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis Late-breaking oral presentation highlighted robust clinical responses with AlloNK plus rituximab across 31 patients with rheumatologic diseases Rheumatoid arthritis data showed clinically meaningful responses in…
/PRNewswire/ -- USA News Group Market Commentary - Start with the number that makes everyone do a double take. As of mid-May 2026, GT Biopharma (NASDAQ: GTBP)
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ARTV.
U.S. House Trading
No House trades found for ARTV.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.